Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Parkinson disease progression measures in health services data: laying the groundwork for studying exposure to PGK1as and Parkinson disease in randomized controlled trials

FY 2023-24

Summary
Parkinson's disease (PD) is the fastest brain disorder to grow in prevalence, disability and death worldwide. It leads to tremors, difficulty with walking, talking and thinking. Until now, no cures for PD exist. Developing a drug "from scratch" is expensive and takes time. "Drug repurposing" is a process by which researchers take a drug already used for a given disease, and apply it to a new condition. Phosphoglycerate kinase 1 activators (PGK1as) are a group of drugs commonly used in prostate disease that have also been shown to slow down brain cell death when tested in the laboratory. Using human real-world data, my team and I recently discovered that PGK1as were associated with a decreased risk of developing PD. What still remains unknown is whether PGK1as can slow down PD progression once the disease has already occurred. Ultimately, this question will need to be studied in a randomized controlled trial (RCT). The goal of my thesis is to use Ontario health services data to lay the foundation for studying PGK1as and PD progression in a future RCT, by answering the "Who", "How" and "What" questions. First, I will explore whether PD patients seen by neurologists in an academic center (and thus likely to be enrolled in RCTs) are similar to all the PD patients in Ontario ("Who"). Second, I will evaluate whether existing measures of PD severity can also accurately capture long-term PD progression defined using outcomes collected in the health services database ("How"). Third, I will test the effectiveness of PGK1as on PD progression in the real-world setting by using statistical methods that can mimic an RCT ("What"). If we find that PGK1as are indeed potentially able to decrease PD progression using real-world data, this will encourage researchers to perform a formal RCT evaluating the effectiveness of PGK1as as a disease modifying therapy for PD.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
496496
Name
Gros Priti
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
Parkinson disease progression measures in health services data: laying the groundwork for studying exposure to PGK1as and Parkinson disease in randomized controlled trials
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Disease Modifying Therapies; Disease Progression; Health Services Research; Parkinson Disease; Pharmacoepidemiology
Abstract
Parkinson's disease (PD) is the fastest brain disorder to grow in prevalence, disability and death worldwide. It leads to tremors, difficulty with walking, talking and thinking. Until now, no cures for PD exist. Developing a drug "from scratch" is expensive and takes time. "Drug repurposing" is a process by which researchers take a drug already used for a given disease, and apply it to a new condition. Phosphoglycerate kinase 1 activators (PGK1as) are a group of drugs commonly used in prostate disease that have also been shown to slow down brain cell death when tested in the laboratory. Using human real-world data, my team and I recently discovered that PGK1as were associated with a decreased risk of developing PD. What still remains unknown is whether PGK1as can slow down PD progression once the disease has already occurred. Ultimately, this question will need to be studied in a randomized controlled trial (RCT). The goal of my thesis is to use Ontario health services data to lay the foundation for studying PGK1as and PD progression in a future RCT, by answering the "Who", "How" and "What" questions. First, I will explore whether PD patients seen by neurologists in an academic center (and thus likely to be enrolled in RCTs) are similar to all the PD patients in Ontario ("Who"). Second, I will evaluate whether existing measures of PD severity can also accurately capture long-term PD progression defined using outcomes collected in the health services database ("How"). Third, I will test the effectiveness of PGK1as on PD progression in the real-world setting by using statistical methods that can mimic an RCT ("What"). If we find that PGK1as are indeed potentially able to decrease PD progression using real-world data, this will encourage researchers to perform a formal RCT evaluating the effectiveness of PGK1as as a disease modifying therapy for PD.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gros, Priti
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~